AB0681 Bisphenol A Levels in Patients with Ankylosing Spondylitis and Its Correlation with Disease Activity

Abstract

Background Ankylosing spondilitis (AS) is a systemic chronic inflammatory disorder of unidentified etiology. Bisphenol A (BPA) which act as a protective lining on the inside of metal-based food and beverage cans, is a chemical produced in large quantities for use primarily in the production of polycarbonate plastics such as hard plastic bottles and epoxy resins. BPA is an estrogenic endocrine disruptor that exerts an extensive variety of metabolic effects. Objectives The objective of present study was to measure serum BPA levels in patients with AS and to explore a possible link between serum BPA levels and disease activity scores. Methods A total of 50 AS patients (40 male, 10 female, mean age 41.14±11.65 years, mean body mass index 26.78±3.94 kg/m2) and 30 age-sex- and body mass index-matched healthy controls (23 male, 7 female, mean age 41.44±6.98, mean body mass index 27±3.06 kg/m2) were taken to the study. Disease activity of the AS patients was measured by Bath ankylosing spondylitis disease activity index (BASDAI). Results The median disease duration of the AS patients was 10.68±10.43 years. Forty-three patients were taking NSAID and/or DMARD. Seven patients were taking an anti-TNF agent. Serum BPA levels of the patients with AS was significantly higher than that of healthy controls (3.98±2.35 vs. 0.49±0.29; p=0.001). There was significant positive correlation between the serum BPA levels and BASDAI scores (r=0.321, p=0.025). Conclusions These data clearly show that serum BPA levels are significantly higher in patients with AS in comparison to age-sex-BMI-matched healthy controls. Furthermore, levels of BPA in AS patients were positively correlated with disease activity scores. References Ozgocmen S, Akgul O, Altay Z, et al. Expert opinion and key recommendations for the physical therapy and rehabilitation of patients with ankylosing spondylitis. International journal of rheumatic diseases 2012;15(3):229-38. Vandenberg LN, Maffini MV, Sonnenschein C, Rubin BS, Soto AM. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocrine reviews 2009;30(1):75-95. Rogers JA, Metz L, Yong VW. Review: Endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms. Molecular immunology 2013;53(4):421-30. Wells EM, Jackson LW, Koontz MB. Association between bisphenol A and waist-to-height ratio among children: National Health and Nutrition Examination Survey, 2003-2010. Annals of epidemiology 2013. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.1383

Anti-tumor necrosis factor alpha treatment does not influence serum levels of the markers associated with radiographic progression in ankylosing spondylitis

“…[ 23 ] In a study investigating whether the SOST level was affected by anti-TNF-α in AS patients, in which patients who received and did not receive anti-TNF-α therapy were cross-sectionally evaluated, the SOST level did not differ, similar to our results. [ 7 ] In a study investigating whether the SOST level was affected by anti-TNF-α in AS patients, in which patients who received and did not receive anti-TNF-α were evaluated cross-sectionally, the SOST level did not differ, similar to our results. [ 7 ] In another study, SOST levels were observed to be low in AS patients, unlike in our study, and it was asserted that this might be associated with persistent inflammation and poor response to anti-TNF-α treatment.…”

“…[ 7 ] In a study investigating whether the SOST level was affected by anti-TNF-α in AS patients, in which patients who received and did not receive anti-TNF-α were evaluated cross-sectionally, the SOST level did not differ, similar to our results. [ 7 ] In another study, SOST levels were observed to be low in AS patients, unlike in our study, and it was asserted that this might be associated with persistent inflammation and poor response to anti-TNF-α treatment. [ 24 ] However, since the mean disease durations of the patients included in this study are not known, it did not seem possible to make a direct comparison with our study, considering the possible changes in these biomarkers with disease duration.…”

“…[ 5 ] In the literature, there are studies indicating that DKK-1 and SOST levels are lower in AS patients in comparison to control subjects. [ 6 , 7 ]…”

Serum DKK-1 level in ankylosing spondylitis: insights from meta-analysis and Mendelian randomization

“…In subsequent studies on the serological level of DKK-1 in patients with AS, some studies ( 17 , 20 , 22 , 24 , 26 – 28 , 44 , 47 , 49 , 51 – 53 , 55 , 56 , 59 , 60 , 62 ) also demonstrated lower serum DKK-1 levels in patients than in controls. In contrast, some studies ( 15 , 16 , 18 , 21 , 23 , 25 , 43 , 45 , 48 – 50 , 57 , 58 , 63 ) have reported that the serum level of DKK-1 in patients was higher than that in controls.…”

The TNF-NF-κB-DKK1 Axis Promoted Bone Formation in the Enthesis of Ankylosing Spondylitis

“…Dickkopf 1 (DKK1) is an inhibitory molecule of the Wnt/β-catenin signaling pathway, which can stimulate new bone formation by regulating osteoblastogenesis and osteoclastogenesis [ 7 ]. Since new bone formation is a key pathological feature of AS, several efforts have been made to elucidate whether DKK1 is involved in pathogenesis of AS [ 8 - 11 ]. However, previous studies have shown controversial results regarding the serum DKK1 levels in AS patients [ 12 , 13 ].…”